Marksans Pharma has successfully established itself as a trustworthy name in the pharmaceutical world. Our success is attributed to our unwavering focus and exceptional execution strategies. By concentrating our efforts on key areas, we were able to drive market share growth across various products and SKUs. Additionally, we experienced robust growth across all the markets we operate in.
Strategic low-cost manufacturing, active product registrations and front-end distribution have played an instrumental role in helping Marksans expand its business across key international markets. Our 4 world-class and accredited manufacturing units along with 4 highly capable R&D centres have propelled us toward rapid growth and success.
At Marksans, we firmly believe that integrating sustainability into our business operations is not only the right thing to do but also essential for long-term success. In order to achieve this, we have been taking initiatives to enhance our environmental, social, and governance performance. Towards our environmental efforts, we have been implementing initiatives to ensure the efficient use of resources and minimise waste generation. By optimising our resource utilisation, we strive to reduce our environmental footprint and contribute to a more sustainable future.
Additionally, we have placed a strong emphasis on energy conservation measures. Regular reviews of energy generation and consumption allow us to identify areas for improvement and effectively control our energy utilisation. Through these efforts, we aim to reduce our carbon footprint and mitigate the impact of our operations on the environment.
We are committed to our goal of expanding our operations, improving our margins over the next couple of years, and delivering superior returns for our shareholders.
We will also continue our focus on revenue growth by growing our product basket. We aim to launch new high-margin products, enter new geographies, add new customers, and capture growth opportunities in the OTC segment.
An important aspect of our growth strategy is the backward integration into active pharmaceutical ingredient (API) manufacturing for our core molecules. By enduring into the CDMO Model, we can ensure a secure supply chain and enhance our control over the quality and cost of our products. This strategic move also aligns with our goal of operational efficiency and self-sufficiency.